DK2275103T3 - mTor-inhibitorer ved behandling af endokrine tumorer - Google Patents

mTor-inhibitorer ved behandling af endokrine tumorer

Info

Publication number
DK2275103T3
DK2275103T3 DK10175197.2T DK10175197T DK2275103T3 DK 2275103 T3 DK2275103 T3 DK 2275103T3 DK 10175197 T DK10175197 T DK 10175197T DK 2275103 T3 DK2275103 T3 DK 2275103T3
Authority
DK
Denmark
Prior art keywords
treatment
mtor inhibitors
endocrine tumors
endocrine
tumors
Prior art date
Application number
DK10175197.2T
Other languages
English (en)
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2275103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2275103T3 publication Critical patent/DK2275103T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10175197.2T 2005-11-21 2006-11-20 mTor-inhibitorer ved behandling af endokrine tumorer DK2275103T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14
EP08162295A EP2022498A3 (en) 2005-11-21 2006-11-20 Neuroendocrine tumour treatment

Publications (1)

Publication Number Publication Date
DK2275103T3 true DK2275103T3 (da) 2014-07-07

Family

ID=37671355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10175197.2T DK2275103T3 (da) 2005-11-21 2006-11-20 mTor-inhibitorer ved behandling af endokrine tumorer

Country Status (22)

Country Link
US (3) US9006224B2 (da)
EP (3) EP2275103B1 (da)
JP (3) JP2009516671A (da)
KR (2) KR20140012218A (da)
CN (1) CN103446138A (da)
AU (2) AU2006314444C1 (da)
BR (1) BRPI0618808A2 (da)
CA (2) CA2933875C (da)
CY (1) CY1115299T1 (da)
DK (1) DK2275103T3 (da)
ES (1) ES2481671T3 (da)
HK (1) HK1150746A1 (da)
HR (1) HRP20140708T1 (da)
IL (3) IL191475A (da)
MA (1) MA29966B1 (da)
NO (4) NO20220050A1 (da)
NZ (1) NZ568182A (da)
PL (1) PL2275103T3 (da)
PT (1) PT2275103E (da)
RU (1) RU2487711C2 (da)
SI (1) SI2275103T1 (da)
WO (1) WO2007057457A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762140B1 (en) 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US9057054B2 (en) 2009-06-25 2015-06-16 The Regents Of The University Of Michigan Antigen-specific long-term memory T-cells
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
PT3050882T (pt) 2010-03-10 2018-04-16 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
EP2961408A1 (en) * 2013-02-28 2016-01-06 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
WO2014144405A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2017000085A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Sunlidac在制备抗肺癌产品中的应用
CA3011982A1 (en) * 2016-01-21 2017-07-27 Chiasma Inc. Oral octreotide for the treatment of disease
EP3618867A4 (en) 2017-05-02 2021-01-20 Cornell University METHODS AND REAGENTS FOR AGAINST TUMOR WITH HIGHER EFFICIENCY AND LOWER TOXICITY
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019157363A2 (en) * 2018-02-09 2019-08-15 Mount Tam Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
JP7381492B2 (ja) 2018-05-01 2023-11-15 レヴォリューション・メディスンズ，インコーポレイテッド Ｍｔｏｒ阻害剤としてのｃ２６－連結ラパマイシン類似体
AU2019262978B2 (en) 2018-05-01 2023-07-13 Revolution Medicines, Inc. C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
US20220184084A1 (en) * 2019-03-18 2022-06-16 The Regents Of The University Of California Compositions and methods for treating cushing's disease
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3220332A1 (en) * 2021-06-07 2022-12-15 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (da) 1992-04-03 1994-06-21 Ciba Geigy Ag
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
PT836605E (pt) 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
EP0896544B1 (en) * 1996-06-11 2003-02-26 Novartis AG Combination of a somatostatin analogue and a rapamycin
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
US5932613A (en) 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
BR0009507A (pt) 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
CA2383451A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
RU2264405C2 (ru) 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
MXPA03004037A (es) 2000-11-07 2003-08-19 Novartis Ag Derivados de indolilmaleimida como inhibidores de proteina de cinasa c.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
PL363991A1 (en) * 2001-04-06 2004-11-29 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
MXPA03010907A (es) * 2001-06-01 2004-02-17 Wyeth Corp Combinaciones antineoplasicas.
US20030008923A1 (en) 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EA008379B1 (ru) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
HUP0500844A2 (en) 2002-12-09 2007-08-28 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3(jak3)
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20070167478A1 (en) 2003-12-22 2007-07-19 Anne Boulay Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
MXPA06007640A (es) 2004-01-12 2007-04-17 Cytopia Res Pty Ltd Inhibidores de quinasa selectivos.
US7749698B2 (en) 2004-02-23 2010-07-06 Novartis Ag p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
BRPI0507834A (pt) * 2004-02-23 2007-07-10 Sugen Inc método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor
EP1827437B1 (en) * 2004-12-15 2011-11-02 Novartis AG Combinations of therapeutic agents for treating cancer
WO2006071966A2 (en) * 2004-12-29 2006-07-06 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1

Also Published As

Publication number Publication date
BRPI0618808A2 (pt) 2011-09-13
EP2022498A3 (en) 2012-08-15
EP1954269A2 (en) 2008-08-13
IL250697A0 (en) 2017-04-30
KR20080071600A (ko) 2008-08-04
WO2007057457A2 (en) 2007-05-24
EP2275103A3 (en) 2011-10-12
KR20140012218A (ko) 2014-01-29
PT2275103E (pt) 2014-07-24
AU2006314444C1 (en) 2018-01-04
US20080255029A1 (en) 2008-10-16
IL191475A (en) 2017-08-31
HK1150746A1 (en) 2012-01-13
EP2275103B1 (en) 2014-04-23
CA2629245A1 (en) 2007-05-24
NO344288B1 (no) 2019-10-28
JP2013144706A (ja) 2013-07-25
JP5963836B2 (ja) 2016-08-03
CN103446138A (zh) 2013-12-18
CA2933875C (en) 2018-06-26
NO346575B1 (no) 2022-10-17
AU2010202866A1 (en) 2010-07-29
CA2629245C (en) 2016-07-12
NO20220050A1 (no) 2008-08-12
IL253698A0 (en) 2017-09-28
NO20161045A1 (no) 2008-08-12
NO341023B1 (no) 2017-08-07
JP2015061868A (ja) 2015-04-02
US20170128425A1 (en) 2017-05-11
JP5833048B2 (ja) 2015-12-16
PL2275103T3 (pl) 2014-09-30
ES2481671T3 (es) 2014-07-31
HRP20140708T1 (hr) 2014-09-26
US20150148294A1 (en) 2015-05-28
AU2006314444A1 (en) 2007-05-24
EP2022498A2 (en) 2009-02-11
SI2275103T1 (sl) 2014-07-31
MA29966B1 (fr) 2008-11-03
NO20170956A1 (no) 2008-08-12
CA2933875A1 (en) 2007-05-24
WO2007057457A3 (en) 2008-01-10
RU2487711C2 (ru) 2013-07-20
CY1115299T1 (el) 2017-01-04
NO20082683L (no) 2008-08-12
JP2009516671A (ja) 2009-04-23
NZ568182A (en) 2010-08-27
AU2006314444B2 (en) 2010-08-26
EP2275103A2 (en) 2011-01-19
RU2008124827A (ru) 2009-12-27
US9006224B2 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
DK2275103T3 (da) mTor-inhibitorer ved behandling af endokrine tumorer
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2100614T3 (da) Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
DE602005002517D1 (de) Drehtisch
DK1951724T3 (da) Sammensmeltede bicykliske mTOR-inhibitorer
DK1859793T3 (da) Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer
ATE446090T1 (de) Thiadiazolidinone als gsk3-inhibitoren
CY2200156T2 (el) Επεξεργασια λυματων
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
DE602006019395D1 (de) Media-behandlungseinrichtung
ATE493403T1 (de) Kinaseinhibitoren
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
DK1713805T3 (da) Kinaseinhibitorer
DK1803456T5 (da) Farmaceutiske sammensætninger omfattende L-733060 til anvendelse ved behandling af cancertumorer
ITMO20050254A1 (it) Gruppo abrasivo
FI20040011A (fi) Menetelmä pintojen käsittelemiseksi
DE112005002873A5 (de) Meerwasserentsalzungsanlage
DK1933840T3 (da) Anvendelse af delmopinol i behandlingen af acne
DK1765832T3 (da) Hidtil ukendte oxabispidinforbindelser deres anvendelse til behandling af hjertearytmier
DK2120919T3 (da) Ny kombination til anvendelse ved behandling af inflammatoriske lidelser
DE602005002391D1 (de) Schwenkbarer Drehtisch
DK2107906T3 (da) Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier